Market Cap 537.42M
Revenue (ttm) 263.40M
Net Income (ttm) -198.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -75.51%
Debt to Equity Ratio 0.00
Volume 1,425,600
Avg Vol 1,898,398
Day's Range N/A - N/A
Shares Out 73.42M
Stochastic %K 81%
Beta 2.22
Analysts Strong Sell
Price Target $18.58

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
buyandsold
buyandsold Aug. 23 at 8:16 PM
$ARVN i think we could see $7.90 on Monday as the Logos letter highlights the value. Even if we can only get $5 dividend we'd be in great shape
0 · Reply
MomentumSpark
MomentumSpark Aug. 23 at 6:02 AM
$ARVN Arvinas Inc is a protein degradation company with promising oncology platform and partnerships
1 · Reply
buyandsold
buyandsold Aug. 23 at 12:48 AM
$ARVN Logos has politely requested a $9.60 dividend, a 5 for 1 reverse split, and a lean approach to the future. I approve this message.
0 · Reply
TwongStocks
TwongStocks Aug. 22 at 8:52 PM
$ARVN Logos Global Management filed a 13D. https://www.sec.gov/Archives/edgar/data/1655759/000093583625000557/xslSCHEDULE_13D_X01/primary_doc.xml Reporting beneficial ownership of 6.3m shares, 8.6%. Under Item 3, they disclosed buying 3,200,000 shares on the open market from May 1 - August 18 for a total purchase price of $23,534,011.75. Under Item 4, they disclosed some communication with the company: • Jun 10 they sent an email recommending a strategic reset of the company's direction and structure • Aug 7 they sent a letter to the board requesting (i) return $700 million of capital to stockholders, (ii) substantially reduce operating expenses and right-size the organization, (iii) allow the company's valuation to rebase around its core science, (iv) execute a 1-for-5 reverse stock split to facilitate institutional re-engagement, and (v) rebuild the company's credibility through disciplined capital allocation and business development.
1 · Reply
buyandsold
buyandsold Aug. 18 at 4:44 AM
$ARVN may just burn cash until Vepdeg approval. And then what? Cant imagine why they cant find a CEO.
1 · Reply
diegosan21
diegosan21 Aug. 15 at 8:21 PM
Strong week 🦾🦾🚀 $SRPT $APLS $AAL $ARVN
0 · Reply
diegosan21
diegosan21 Aug. 15 at 4:44 PM
$SRPT $APLS $ARVN looking great today
0 · Reply
sullivan_schwartz81
sullivan_schwartz81 Aug. 14 at 4:59 PM
$ARVN UTRX isn’t “exposed” to BTC… they’re LIVING in it Every sat mined = more LIQ, more deals, more upside 🚀 You think this stays a $3M mcap when BTC runs? LMAO.
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 14 at 2:13 PM
$VSTM added. fda approved product + G12D inhibitor - very undervalued imho. $RVMD $ARVN $ERAS $ELTX
1 · Reply
buyandsold
buyandsold Aug. 13 at 9:25 PM
$ARVN what does the lame duck CEO do all day besides snacking on haggis and sticking pins in his Pfizer voodoo doll. Maybe he is drafting a second off cycle options award to make bank of the lows he has taken us to. Maybe he writing a white paper seeking to redefine what "best in class" means. Perhaps he is wondering why shareholders keep sending him liquidizers from Amazon.
0 · Reply
Latest News on ARVN
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:24 PM EDT - 17 days ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript


Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 3 months ago

Arvinas to Present at Jefferies Global Healthcare Conference


Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:40 PM EDT - 4 months ago

Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript


buyandsold
buyandsold Aug. 23 at 8:16 PM
$ARVN i think we could see $7.90 on Monday as the Logos letter highlights the value. Even if we can only get $5 dividend we'd be in great shape
0 · Reply
MomentumSpark
MomentumSpark Aug. 23 at 6:02 AM
$ARVN Arvinas Inc is a protein degradation company with promising oncology platform and partnerships
1 · Reply
buyandsold
buyandsold Aug. 23 at 12:48 AM
$ARVN Logos has politely requested a $9.60 dividend, a 5 for 1 reverse split, and a lean approach to the future. I approve this message.
0 · Reply
TwongStocks
TwongStocks Aug. 22 at 8:52 PM
$ARVN Logos Global Management filed a 13D. https://www.sec.gov/Archives/edgar/data/1655759/000093583625000557/xslSCHEDULE_13D_X01/primary_doc.xml Reporting beneficial ownership of 6.3m shares, 8.6%. Under Item 3, they disclosed buying 3,200,000 shares on the open market from May 1 - August 18 for a total purchase price of $23,534,011.75. Under Item 4, they disclosed some communication with the company: • Jun 10 they sent an email recommending a strategic reset of the company's direction and structure • Aug 7 they sent a letter to the board requesting (i) return $700 million of capital to stockholders, (ii) substantially reduce operating expenses and right-size the organization, (iii) allow the company's valuation to rebase around its core science, (iv) execute a 1-for-5 reverse stock split to facilitate institutional re-engagement, and (v) rebuild the company's credibility through disciplined capital allocation and business development.
1 · Reply
buyandsold
buyandsold Aug. 18 at 4:44 AM
$ARVN may just burn cash until Vepdeg approval. And then what? Cant imagine why they cant find a CEO.
1 · Reply
diegosan21
diegosan21 Aug. 15 at 8:21 PM
Strong week 🦾🦾🚀 $SRPT $APLS $AAL $ARVN
0 · Reply
diegosan21
diegosan21 Aug. 15 at 4:44 PM
$SRPT $APLS $ARVN looking great today
0 · Reply
sullivan_schwartz81
sullivan_schwartz81 Aug. 14 at 4:59 PM
$ARVN UTRX isn’t “exposed” to BTC… they’re LIVING in it Every sat mined = more LIQ, more deals, more upside 🚀 You think this stays a $3M mcap when BTC runs? LMAO.
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 14 at 2:13 PM
$VSTM added. fda approved product + G12D inhibitor - very undervalued imho. $RVMD $ARVN $ERAS $ELTX
1 · Reply
buyandsold
buyandsold Aug. 13 at 9:25 PM
$ARVN what does the lame duck CEO do all day besides snacking on haggis and sticking pins in his Pfizer voodoo doll. Maybe he is drafting a second off cycle options award to make bank of the lows he has taken us to. Maybe he writing a white paper seeking to redefine what "best in class" means. Perhaps he is wondering why shareholders keep sending him liquidizers from Amazon.
0 · Reply
Estimize
Estimize Aug. 13 at 10:00 AM
Wall St is expecting -0.75 EPS for $ARVN Q3 [Reporting 11/11 BMO] http://www.estimize.com/intro/arvn?chart=historical&metric_name=eps&utm_c
0 · Reply
Seanwishwise
Seanwishwise Aug. 12 at 6:06 PM
Tracking: $ARVN $LUNR GRRR $SRPT CODI $ASTS watchlist is on course 🤩!
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 12 at 12:46 PM
$ARVN KRAS G12D asset worth ~$1B by itself, yet Arvinas is trading below cash. investors aren't very smart. https://endpoints.news/bayer-licenses-early-stage-kras-cancer-drug-from-kumquat-for-up-to-1-3b/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=
1 · Reply
Buyitall2024
Buyitall2024 Aug. 11 at 2:30 PM
$ARVN why so slow ?
2 · Reply
G101SPM
G101SPM Aug. 11 at 10:03 AM
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 11 at 10:02 AM
WATCHLIST AUG 11 2025. $ARVN Arvinas And Pfizer Announce FDA Accepts New Drug Application For Vepdegestrant For Treatment Of ESR1m, ER+/HER2- Advanced Breast Cancer $TTD Scotiabank Maintains Sector Perform on Trade Desk, Lowers Price Target to $60 $BMNR Bitmine Immersion Technologies shares are trading higher after the company earlier this week announced it has accumulated 833,137 ETH, valued at nearly $3 billion. $LLY Sitryx Regains Rights To SYX-1042 Itaconate Mimetic For Chronic Autoimmune And Inflammatory Diseases From Lilly Following Portfolio Reprioritization $MKTX Jefferies Maintains Hold on MarketAxess Holdings, Lowers Price Target to $208
0 · Reply
Tabinvest
Tabinvest Aug. 10 at 1:10 PM
$ARVN https://www.marketbeat.com/instant-alerts/arvinas-nasdaqarvn-releases-quarterly-earnings-results-beats-estimates-by-003-eps-2025-08-08/
0 · Reply
Tabinvest
Tabinvest Aug. 10 at 1:08 PM
$ARVN Institutional investors hold over 95% of shares and HC Wainwright: Reduced to $18.00 (Buy) Guggenheim: Cut to $15.00 (Buy)
0 · Reply
Buyitall2024
Buyitall2024 Aug. 9 at 6:27 PM
$ARVN so PT AROUND 30-40 by END OF AUGUST 🤞
0 · Reply
biopuzzle
biopuzzle Aug. 9 at 5:40 PM
$ARVN NDA for Vepdegestrant is accepted by FDA. PDUFA date 06/05/2026. Fast Track designation.
1 · Reply
Buyitall2024
Buyitall2024 Aug. 9 at 1:39 PM
$ARVN so when will they get the milestone money? Since it been accepted by FDA . Can they get some now ?
1 · Reply
gilheydari
gilheydari Aug. 8 at 10:42 PM
$ARVN 8M share shorted here and institutional ownership is high, They are afraiding of price spike, this is the reason of that wall. lets see how long they can control the pricing here. Enterprise value at -400M is a joke
0 · Reply